Iron Homeostasis In Neurodegeneration plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Iron homeostasis is critical for normal brain function, as iron is an essential cofactor for oxidative phosphorylation, neurotransmitter synthesis, and myelin production. However, dysregulated iron metabolism is a hallmark feature of multiple neurodegenerative diseases, including Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). Iron accumulation in specific brain regions correlates with disease progression and severity, making iron homeostasis a key therapeutic target.
Iron balance in the body is tightly controlled through hepcidin-mediated regulation:
flowchart TD
subgraph Systemic_Iron
A[Intestinal Iron<br>Absorption] --> B[Transferrin] -->
B --> C[Non-transferrin-bound<br>Iron NTBI] -->
C --> D[Ferritin<br>Storage] -->
D --> E[Brain Iron<br>Entry]
end
subgraph Brain_Iron
E --> F[Divalent Metal<br>Transporter 1 DMT1] -->
F --> G[Neurons)
F --> H[Oligodendrocytes)
F --> I[Microglia)
end
J[Hepcidin] -.->|Regulates| A
J -.->|Regulates| F
style A fill:#E6F3FF
style G fill:#FFE6E6
style J fill:#90EE90
| Protein |
Function |
Brain Expression |
| Transferrin (TF) |
Iron transport in blood and CSF |
Produced in choroid plexus |
| Ferritin (FTL/FTH) |
Iron storage |
All neural cell types |
| DMT1 |
Ferrous iron transporter |
Neurons, oligodendrocytes |
| Ferroportin (FPN) |
Iron export |
Neurons, microglia, endothelial cells |
| Hepcidin (HAMP) |
Systemic iron regulation |
Limited brain expression |
| IRP/IRE system |
Post-transcriptional iron regulation |
Ubiquitous |
Parkinson's disease is characterized by dramatic iron accumulation in the substantia nigra pars compacta (SNpc), particularly in neuromelanin-containing dopaminergic neurons:
- Iron levels in SNpc are 2-3 times higher in PD patients compared to age-matched controls
- Iron accumulation correlates with loss of dopaminergic neurons
- Ferritin expression is increased in microglia surrounding degenerating neurons
flowchart TD
subgraph PD_Iron_Dysregulation
A[α-Synuclein<br>Aggregation] --> B[Iron Binding] -->
B --> C[Enhanced Iron<br>Internalization] -->
C --> D[Mitochondrial<br>Iron Overload] -->
D --> E[ROS Generation] -->
E --> F[Lipid Peroxidation] -->
F --> G[Neuronal Death] -->
H[Parkin Mutation] --> I[Impaired<br>Ferroportin Function] -->
I --> C
J[PINK1 Mutation] --> K[Mitophagy<br>Dysfunction] -->
K --> D
end
style A fill:#FFE6E6
style G fill:#FF6B6B
Dopaminergic neurons are particularly vulnerable to iron toxicity due to:
- Oxidative metabolism: Dopamine oxidation generates H₂O₂, which reacts with iron via Fenton chemistry
- Neuromelanin: Binds iron but becomes saturated in PD, releasing free iron
- Mitochondrial density: High mitochondrial content increases ROS production in presence of iron
Iron accumulates in brain regions affected by AD pathology:
- Hippocampus: Iron co-localizes with amyloid plaques and neurofibrillary tangles
- Cortex: Iron in neurons and microglia, associated with amyloid deposits
- Choroid plexus: Dysregulated iron transport across BBB
¶ Iron and Amyloid Interaction
flowchart TD
subgraph Iron_Aβ_Interaction
A[APP/ABAD<br>Interaction] --> B[Mitochondrial<br>Iron Overload] -->
B --> C[ROS<br>Generation] -->
C --> D[Enhanced Aβ<br>Production] -->
D --> E[Aβ<br>Aggregation] -->
E --> F[Plaque<br>Formation] -->
G[Iron Response<br>Elements] --> H[IRP Binding<br>to APP mRNA] -->
H --> I[Increased APP<br>Translation] -->
I --> D
F --> C
end
style B fill:#FFE6E6
style F fill:#FF6B6B
Ferroptosis, an iron-dependent form of non-apoptotic cell death, contributes to neuronal loss in AD:
- GPX4 downregulation: Reduced glutathione peroxidase 4 activity
- Lipid peroxidation: Iron-catalyzed oxidation of polyunsaturated fatty acids
- System Xc⁻ dysfunction: Cystine/glutamate antiporter impairment
- Iron accumulation in striatum and cortex
- Mutant huntingtin impairs iron regulatory protein function
- Increased DMT1 expression in vulnerable regions
- Iron accumulation in motor neurons and spinal cord
- Dysregulated ferritin expression in astrocytes
- Iron-responsive element binding protein alterations
- Iron accumulation in olivary nuclei and basal ganglia
- Co-localization with oligodendroglial cytoplasmic inclusions
| Agent |
Mechanism |
Clinical Status |
| Deferoxamine (DFO) |
Binds Fe³⁺ systemically |
Phase II trial (PD); mixed results |
| Deferasirox (DFX) |
Oral iron chelator |
Preclinical |
| Clioquinol |
Cu/Zn chelator with effects on Fe |
Phase II (AD) - slowed cognitive decline |
| PBT2 |
Metal-protein attenuation |
Phase II (AD, HD) - failed primary endpoints |
- DMT1 inhibitors: Block excessive iron entry into neurons
- Ferroportin activators: Enhance iron export
- Ferroptosis inhibitors: Liproxstatin-1, vitamin E
- Antioxidants: CoQ10, N-acetylcysteine
- Iron-sulfur cluster donors: Restore mitochondrial function
- MRI (R2)*: Quantitative susceptibility mapping for brain iron
- Transcranial Sonography: Hyperechogenicity of substantia nigra
- Serum ferritin: Elevated in PD progression
- Transferrin saturation: Altered in neurodegenerative diseases
- Hepcidin levels: Dysregulated in AD and PD
Iron Homeostasis In Neurodegeneration plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Iron Homeostasis In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Zecca L, et al. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004
- Weinreb O, et al. Novel therapeutic strategies for Parkinson's disease: focus on iron. CNS Drugs. 2007
- Ward RJ, et al. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014
- Muckenthaler MU, et al. A Red carpet for iron metabolism. Cell. 2017
- Belaidi AA, Bush AI. Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics. J Neurochem. 2016
- Raha AA, et al. Iron metabolism in neurodegeneration. Brain Res Bull. 2013
- Zhang Y, et al. Ferroptosis: past, present and future. Cell Death Dis. 2020
- Kurant Z, et al. Iron homeostasis and neurodegeneration. Mol Psychiatry. 2022
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
8 references |
| Replication |
0% |
| Effect Sizes |
50% |
| Contradicting Evidence |
67% |
| Mechanistic Completeness |
50% |
Overall Confidence: 42%